Zydus inks agreement with CVS Caremark to add Zituvio, Zituvimet and Zituvimet XR to its template formulary

These three NDAs of Sitagliptin (base) and combination franchise have been approved by the USFDA earlier through the 505(b)(2) route

Briefs: Zydus Lifesciences and Divi's Laboratories

Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets

SMS Pharmaceuticals reports robust Q2FY24 operational performance

Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore

Glenmark to launch a Triple-drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 diabetes

Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually

Akums gets approval for triple combination diabetes treatment

CARE reaffirms A+ rating to IOL Chemicals and Pharmaceuticals

The 'A+' rating reflects IOL's robust business model, diversified product portfolio

Quantumzyme receives patent for development of green catalyst in India

The patent was granted for creating a green catalyst for one of the world's most significant chemical reactions

Glenmark launches Triple FDC of Teneligliptin with Pioglitazone and Metformin for adults with Type 2 Diabetes

This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation

Biocon Q2FY23 net profit slips 10% to Rs 168 Cr; Revenue up 26%

IOL Chemicals and Pharmaceuticals Q2FY23 net profit drops to Rs 15.6 Cr

The company registered with REACH Certificate for Ethyl Acetate with a tonnage band of more than 1000 TPA